Insulet (NASDAQ:PODD) Price Target Raised to $388.00

Insulet (NASDAQ:PODD) had its price target upped by equities research analysts at The Goldman Sachs Group from $375.00 to $388.00 in a report issued on Friday,MarketScreener reports. The firm presently has a “buy” rating on the medical instruments supplier’s stock. The Goldman Sachs Group’s target price indicates a potential upside of 21.32% from the company’s current price.

Several other brokerages also recently weighed in on PODD. Stifel Nicolaus began coverage on shares of Insulet in a research report on Tuesday, October 21st. They set a “buy” rating and a $370.00 price objective for the company. JPMorgan Chase & Co. upped their target price on Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a research report on Friday, September 12th. Zacks Research upgraded Insulet from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 14th. Piper Sandler increased their price objective on Insulet from $320.00 to $360.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Finally, Raymond James Financial lifted their target price on shares of Insulet from $360.00 to $366.00 and gave the company an “outperform” rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Insulet currently has an average rating of “Moderate Buy” and an average target price of $371.38.

Insulet Price Performance

NASDAQ:PODD opened at $319.82 on Friday. The company has a market capitalization of $22.51 billion, a P/E ratio of 97.21, a P/E/G ratio of 2.64 and a beta of 1.39. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. Insulet has a 52 week low of $230.05 and a 52 week high of $353.50. The stock’s fifty day moving average is $325.06 and its two-hundred day moving average is $309.86.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. The company had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm’s quarterly revenue was up 29.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities analysts expect that Insulet will post 3.92 EPS for the current year.

Insiders Place Their Bets

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Prem Singh sold 687 shares of the business’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.39% of the company’s stock.

Institutional Investors Weigh In On Insulet

Several institutional investors and hedge funds have recently made changes to their positions in PODD. Larson Financial Group LLC grew its position in shares of Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 81 shares during the period. Zions Bancorporation National Association UT purchased a new stake in shares of Insulet during the 1st quarter worth about $26,000. SouthState Corp raised its holdings in Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 76 shares during the period. True Wealth Design LLC lifted its position in Insulet by 288.0% during the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 72 shares in the last quarter. Finally, Kozak & Associates Inc. purchased a new position in shares of Insulet in the 2nd quarter valued at $32,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.